Specialty Oncology CRO Medelis is a boutique oncology-focused CRO with end-to-end capabilities in preclinical to phase 3 trials across North America and Europe, presenting a potential partner for sponsors needing specialized oncology execution and strategic trial design.

Early Phase Expertise Strong emphasis on early-phase oncology trials including immunotherapy, offering sponsors access to phase 1/2/3 expertise which can help de-risk first-in-human studies and accelerate onward development.

Global Presence Operations across North America and Europe position Medelis as a bridge for trials requiring cross-border regulatory, site access, and diverse patient populations, enabling global study execution for sponsors.

Recent Thought Leadership Active participation in major industry events such as BIO Europe and ASCO suggests ongoing visibility and potential for introductions to potential partners seeking specialized oncology CRO support.

Growth with Merged Brand Historical merger with WCCT and branding evolution indicate expanded depth of offerings and client base, implying potential for broader service lines and scalable partnerships beyond core CRO activities.